Specialty drugmaker and IBD 50 stock Jazz Pharmaceuticals was up 8% in early afternoon trading on the stock market today after the company late Tuesday beat Q2 estimates and raised its outlook. Jazz Pharmaceuticals (JAZZ) was the last of a group of top drug stocks that reported Q2 earnings on Tuesday, and it wound up with the biggest stock bump of all of them. Leerink analyst Jason Gerberry raised his price target to 181 from 177, noting that the
Specialty drugmaker Jazz Pharmaceuticals (JAZZ) was up 6% in afternoon trading on the stock market today, at a four-month high near 161, after it inked a deal for the American rights to its recently acquired drug defibrotide. Defibrotide, which treats a rare condition called severe hepatic veno-occlusive disease, was developed by Italian biotech Gentium, which Jazz acquired in February. Gentium had licensed the marketing rights in the Americas to
Jazz Pharmaceuticals (JAZZ) got a downgrade — but also several price target hikes — in the wake of its Q4 earnings report late Tuesday, sending the stock plunging, then partly recovering, in the stock market today. Jazz missed Q4 estimates but guided 2014 financials above expectations. Cantor Fitzgerald analyst Irina Rivkind downgraded Jazz stock to hold from buy, focusing on the firm’s ongoing difficulties with the FDA concerning the risk